Cirsium Bio is manufacturing high-quality AAV vectors for genetic medicines in plants. Join this dynamic, innovative team in San Diego! #AAV #viralvectors #opentowork #biotech #sandiegobiotech #molecularbio #cellculture #oncology #SRA #hiring #researchassociate #plantscience
Cirsium Biosciences
生物技术研究
San Diego,CA 1,690 位关注者
Democratizing gene therapy through transformative manufacturing methods
关于我们
Democratizing gene therapy through transformative manufacturing methods
- 网站
-
https://cirsiumbio.com/
Cirsium Biosciences的外部链接
- 所属行业
- 生物技术研究
- 规模
- 11-50 人
- 总部
- San Diego,CA
- 类型
- 私人持股
地点
-
主要
US,CA,San Diego
Cirsium Biosciences员工
-
Daniel G.
Dramatically reducing AAV costs using plants as bioreactors | CEO | Co-Founder @ Cirsium Biosciences
-
Clifford C. David, Jr
Helping Land Owners Generate Revenue by Implementing Environmentally Sustainable Eco-Use Programs
-
Logan Trimble
Downstream Processing Scientist
-
Kevin Wong
Scientist
动态
-
Growing plants for AAV production requires precision beyond just tracking water and soil. Here are a few other key factors we optimize to ensure healthy plant growth: ?? Plant Appearance: Assessing leaf and stem condition to ensure optimal growth. ?? Plant Weight: Tracking biomass to optimize yield and efficiency. ?? Light Spectrums: Adjusting wavelengths to meet plants' specific needs and enhance production. These are just a few of the many factors we carefully monitor to keep our plants thriving for AAV production!
-
-
Today is Rare Disease Day—a reminder of how much work still needs to be done. Rare diseases aren’t actually rare. ?? They affect over 300 million people worldwide and 25–30 million Americans. ?? There are 7,000+ rare diseases, and 90% of them don’t have an FDA-approved treatment. And when treatments do exist? The price tags are wild. ?? Lenmeldy (gene therapy for early-onset metachromatic leukodystrophy): $4.25M for a one-time treatment. ?? Hemgenix (gene therapy for hemophilia B): $3.5M per dose. Here’s the problem: developing and manufacturing these treatments is too expensive, too slow, and full of roadblocks. And that means patients—real people—are left waiting. This is exactly why we’re working to remove cost, time, and production bottlenecks from gene therapy manufacturing. The science exists. The therapies work. Now we need to make them accessible. Today, we recognize the patients fighting for better treatments, the scientists pushing boundaries, and the advocates demanding change. Together, we keep pushing forward.
-
-
Next week, Pranav Mathur will be presenting at the Drug Discovery Innovation Programme (DDIP) in San Diego! He’ll be diving into our platform and addressing the topic: ?? Developing Scalable and Cost-Effective Gene Therapies to Reduce Patient Cost, and Enhance Global Outreach This discussion is crucial for addressing existing bottlenecks and our platform's solution to make gene therapies more accessible and affordable for patients worldwide. Check out the full agenda here: https://lnkd.in/e6-FGtce
-
-
The new year brings big changes—35,000 square feet of new production space, to be exact! We’ve been hard at work transforming this space to expand our production capabilities for both pilot and commercial scale. Here’s what’s this will allow us to do: ?? Establishing cGMP operations to scale production. ?? Expanding our platform’s reach to additional viral vectors and vector-based products. ?? Validating more AAV serotypes through head-to-head NHP studies. ??? Check out the video for a full breakdown of this new space and how we’re putting it to work!
-
There are roughly 435,000 unique land plant species on Earth—so why do we use just one to produce AAVs? ?? ?? ?? While plants like wheat or soy might be household names, Nicotiana benthamiana quietly steals the spotlight in gene therapy manufacturing. ?? ?? Click through to see why this under-the-radar plant is the MVP for AAV production.
-
Earlier this month, we had the pleasure of hosting team members from EverGlade Consulting and Aspire Financials for a site visit. Both teams have been invaluable partners in advancing our plant-based AAV manufacturing platform as we scale production. EverGlade Consulting’s expertise in navigating complex funding initiatives has been instrumental in driving our growth, while Aspire Financials’ financial guidance and support have helped ensure a strong foundation for our expansion. We’re grateful for the collaboration and excited for what’s ahead. Thank you to both teams for your tremendous support in helping us accomplish our vision!
-
-
?? "What advice would you give young girls who dream of a career in science?" In celebration of the International Day of Women and Girls in Science, some of the women on our team shared their advice for the next generation of scientists. From embracing failures as part of discovery to finding mentors who inspire you, their words reflect the curiosity, resilience, and passion that drive innovation. Here’s to those paving the way for the next generation of scientists! #InternationalDayOfWomenAndGirlsInScience #February11 #Feb11